It is also possible to infer that for patients with HER2-positive breast carcinoma treated with trastuzumab, the possible deleterious effects of clinical morbidities, older age, and high BMI on the prevalence and severity of cardiotoxicity would be secondary to the cancer stage from a prognostic point of view. Here, ERBB2 is linked to breast carcinoma.